139 related articles for article (PubMed ID: 32409198)
1. PD-1 topographically defines distinct T cell subpopulations in urothelial cell carcinoma of the bladder and predicts patient survival.
Hou W; Xue M; Shi J; Yang M; Zhong W; Fan X; Zeng H; Lai Y; Huang J; Wang B; Lin T
Urol Oncol; 2020 Aug; 38(8):685.e1-685.e10. PubMed ID: 32409198
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
3. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
4. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder.
Wang B; Xie S; Bi J; Liu Z; Zeng H; Huang H; Xue M; He Z; Yang M; Yu H; Huang J; Lin T
Histopathology; 2019 Sep; 75(3):354-364. PubMed ID: 30653702
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
Debatin NF; Bady E; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Müller JH; Vettorazzi E; Plage H; Samtleben H; Klatte T; Hofbauer S; Elezkurtaj S; Furlano K; Weinberger S; Giacomo Bruch P; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke TH; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Blessin NC
Eur Urol; 2024 Jul; 86(1):42-51. PubMed ID: 38383257
[TBL] [Abstract][Full Text] [Related]
6. Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder.
Yang M; Wang B; Hou W; Yu H; Zhou B; Zhong W; Liu Z; Li J; Zeng H; Liu C; Qin H; Lin T; Huang J
Front Immunol; 2022; 13():827457. PubMed ID: 35386697
[TBL] [Abstract][Full Text] [Related]
7. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
11. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
[TBL] [Abstract][Full Text] [Related]
12. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF
Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
14. Microlocalization and clinical significance of stabilin-1
Wang B; Huang H; Yang M; Yang W; Liu Z; Hou W; Zeng H; He Z; Lin T; Huang J
World J Urol; 2020 Mar; 38(3):709-716. PubMed ID: 31302753
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
16. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
17. T lymphocyte subsets and function in the peripheral blood of patients with urological cancer.
Kaver I; Pecht M; Trainin N; Greenstein A; Braf Z
Oncology; 1992; 49(2):108-13. PubMed ID: 1574245
[TBL] [Abstract][Full Text] [Related]
18. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
19. [RBC and T lymphocyte subsets in patients with bladder carcinoma: immunological study].
Xu J; Zhang Y
Zhonghua Wai Ke Za Zhi; 1999 Feb; 37(2):113-6. PubMed ID: 11829798
[TBL] [Abstract][Full Text] [Related]
20. High CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer.
Zhang Q; Hao C; Cheng G; Wang L; Wang X; Li C; Qiu J; Ding K
Int J Clin Exp Pathol; 2015; 8(9):11510-6. PubMed ID: 26617883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
